Evidence map›Paper›PMID 28811600›Full record

ArticleScientific reports2017

Exploring Leishmania secretory proteins to design B and T cell multi-epitope subunit vaccine using immunoinformatics approach.

Nazia Khatoon, Rajan Kumar Pandey, Vijay Kumar Prajapati

Abstract read
In one paragraph

Article in Scientific reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 165 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
165citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

165 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Designing a novel and effective multi-epitope subunit vaccine against human astrovirus using reverse vaccinology approach.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2026
    Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Immunoinformatics analysis of the proteins MPT83 and MPT51 to design a possible chimeric vaccine against Mycobacterium tuberculosis.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2025
    Article
  13. Article
  14. Article
  15. Review
  16. Optimizing a Subunit Vaccine ofIranian journal of public health · 2025
    Article
  17. Article
  18. Article
  19. Article
  20. Article

105 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Nazia KhatoonDepartment of Biochemistry, School of Life Sciences, Central University of Rajasthan, NH-8, Bandarsindri, Kishangarh, 305817, Ajmer, Rajasthan, India.
Rajan Kumar PandeyDepartment of Biochemistry, School of Life Sciences, Central University of Rajasthan, NH-8, Bandarsindri, Kishangarh, 305817, Ajmer, Rajasthan, India.
Vijay Kumar PrajapatiDepartment of Biochemistry, School of Life Sciences, Central University of Rajasthan, NH-8, Bandarsindri, Kishangarh, 305817, Ajmer, Rajasthan, India. vkprajapati@curaj.ac.in.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Visceral leishmaniasis (VL) is a fatal form of leishmaniasis which affects 70 countries, worldwide. Increasing drug resistance, HIV co-infection, and poor health system require operative vaccination strategy to control the VL transmission dynamics. Therefore, a holistic approach is needed to generate T and B memory cells to mediate long-term immunity against VL infection. Consequently, immunoinformatics approach was applied to design Leishmania secretory protein based multi-epitope subunit vaccine construct consisting of B and T cell epitopes. Further, the physiochemical characterization was performed to check the aliphatic index, theoretical PI, molecular weight, and thermostable nature of vaccine construct. The allergenicity and antigenicity were also predicted to ensure the safety and immunogenic behavior of final vaccine construct. Moreover, homology modeling, followed by molecular docking and molecular dynamics simulation study was also performed to evaluate the binding affinity and stability of receptor (TLR-4) and ligand (vaccine protein) complex. This study warrants the experimental validation to ensure the immunogenicity and safety profile of presented vaccine construct which may be further helpful to control VL infection.

Indexed as

Amino Acid SequenceAntigens, ProtozoanCodonComputational BiologyEpitopes, B-LymphocyteEpitopes, T-LymphocyteHumansImmunogenicity, VaccineLeishmaniaLeishmaniasisLeishmaniasis VaccinesModels, MolecularProtein BindingProtein ConformationQuantitative Structure-Activity RelationshipT-LymphocytesAntigens, ProtozoanCodonEpitopes, B-LymphocyteEpitopes, T-LymphocyteLeishmaniasis VaccinesToll-Like Receptor 4Vaccines, Subunit

Identifiers

PMID28811600
PMCPMC5557753

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.